Wan-Fai Ng
University of Newcastle upon Tyne
Walter Maetzler
Universitätsklinikum Schleswig-Holstein
Nikolay Manyakov
Janssen Pharmaceutica NV
Geert Van Gassen
Takeda Pharmaceuticals International AG
David Wenn
iXscient Ltd
Mike Jackson
iXscient Ltd
Dario Masullo
Janssen Pharmaceutica NV
Walter Maetzler
Universitätsklinikum Schleswig-Holstein
Babak Boroojerdi
UCB Biopharma SPRL
Christopher Bull
University of Newcastle upon Tyne
Kenneth Mosca
Janssen Pharmaceutica NV
Teemu Ahmaniemi
Teknologian tutkimuskeskus VTT Oy
Meenakshi Chatterjee
Janssen Pharmaceutica NV
Christoph Kanzler
Biogen IDEC Ltd
Yi-Ke Guo
Imperial College of Science Technology and Medicine
Kai Sun
Imperial College of Science Technology and Medicine
Frédéric Baribaud
Bristol-Myers Squibb Company Corp.
Wan-Fai Ng
University of Newcastle upon Tyne
Nadir Ammour
Sanofi Aventis Recherche et Développement
Walter Maetzler
Universitätsklinikum Schleswig-Holstein
Jérôme Kalifa
Let it Care SAS
Stefan Avey
Janssen Pharmaceutica NV
Evert-Ben van Veen
Stichting MLC Foundation
Ann Marie Hake
Eli Lilly & Co Ltd.
Veli Stroetmann
empirica Gesellschaft für Kommunikations und Technologieforschung Mbh
David Nobbs
F. Hoffmann-La Roche AG
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 853981. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA and PARKINSON’S DISEASE SOCIETY OF THE UNITED KINGDOM LBG.
